Oxford Nanopore reported 22% revenue growth for 2025 while announcing strategic restructuring that narrowed product lines and reduced R&D headcount. The company will discontinue lower‑priority platforms and refocus resources on prioritized opportunities, citing cost discipline and higher demand from production customers. Separately, clinicians at Children’s Hospital of Philadelphia (CHOP) and Seattle Children’s said at AGBT they will implement ultra‑rapid nanopore sequencing assays for acute leukemia and CNS tumor diagnosis, signaling accelerated clinical adoption of nanopore workflows for time‑sensitive oncology cases.